Burrill & Company in San Francisco announced today a new life sciences investment fund with commitments so far totaling $313 million. The company says its Burrill Capital Fund IV plans to make early to late stage investments in therapeutics, diagnostics, medical devices, health care delivery, wellness, and digital health.
CEO G. Steven Burrill says the fund is expected to raise some $500 million total by June 2012. The company claims to have more than $1 billion in assets under management its businesses that include venture capital, private equity, and merchant banking.
Burrill’s venture division specializes in life sciences investments. In addition to investing in enterprises in the human health care field, Burrill also invests in new agricultural biotechnology, biofuels, and industrial biotechnology businesses.
The company says it invests mostly in earlier stage A and B rounds in the U.S. and Europe, although the Burrill Capital Fund IV also plans later stage investments. The average investment made by Burrill is $5 to $15 million over the life of any one company.
Hat tip: Fierce Biotech
Read more: Venture Fund Raises $50M for Life Science Investments
Photo: borman818/Flickr
* * *
You must be logged in to post a comment.